Ertugliflozin was first approved in 2017 for the treatment of type 2 diabetes. This medication is an SGLT2 inhibitor that prevents the resorption of glucose back into systemic circulation. It has been shown to be effective in lowering A1c and managing diabetes. In...
Type II diabetes is a complicated disease state that often requires a combination of medications to control. However, some combinations of antidiabetes medications, such as sulfonylureas and basal insulin, may lead to unintended adverse effects. In this article, we...
Treating patients with type II diabetes often requires an array of medications to control blood sugar and manage various comorbidities. Understanding possible drug-drug and drug-disease interactions between medications is extremely important for optimizing medication...
Reducing diabetes medications in geriatric patients with low A1c involves careful consideration of the risks and benefits of continued intensive glycemic control. In older adults, particularly those with multiple comorbidities, frailty, or limited life expectancy,...
Insulin icodec may have a new competitor in the near future. Insulin efsitora is another once-weekly insulin currently undergoing phase 3 clinical trials, with Lilly’s 3rd phase being termed the QWINT trials (Once Weekly (QW) Insulin Therapy (INT)). These trials are...
The American Thyroid Association defines hypothyroidism as a result of an “underactive thyroid gland.” Common symptoms include fatigue, cold sensitivity, dry skin, weight gain, hair loss, high cholesterol, or constipation. The recommended treatment is replacing the...
